NCT03406611 Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)
| NCT ID | NCT03406611 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Travere Therapeutics, Inc. |
| Condition | Homocystinuria |
| Study Type | INTERVENTIONAL |
| Enrollment | 39 participants |
| Start Date | 2019-01-22 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 39 participants in total. It began in 2019-01-22 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Researchers are looking for a better way to treat people who have classical homocystinuria (HCU), a rare condition that is passed down by parents (or "genetic condition"). It is caused by changes in the cystathionine beta-synthase (or "CBS") gene and prevents an enzyme from working correctly in the body. This enzyme breaks down a substance called homocysteine (from dietary methionine found in protein) and keeps both homocysteine and methionine at normal levels. When this enzyme is not working, homocysteine and methionine build up in the blood, which spreads into different tissues of the body and stops these body tissues from working normally. People with HCU can experience problems with vision, bones, blood vessels, and cognitive function (the ability to think, learn, and remember). Treatments available for HCU, such as a low protein diet and betaine (Cystadane®), help reduce homocysteine levels. The diet is a low methionine diet and a methionine-free protein supplement (a product that provides extra protein to help meet daily protein needs). These treatments are either not sufficient or are hard to take for many patients. Pegtibatinase was developed by scientists to be a version of the CBS enzyme that can be given to people with HCU. Researchers believe that giving pegtibatinase to people with HCU already getting medical treatment (or "standard of care") may reduce their homocysteine levels. This study is split into 7 different groups getting different amounts of drug. The first 6 groups have already finished the study. Group 7 plans to enroll participants from the US (virtual and in-person), France, and Qatar.
Eligibility Criteria
Inclusion Criteria: * Age * Cohort 7 (currently enrolling): ≥5 to \<12 years of age. * Completed Cohorts 1-6: ≥12 to 65 years of age. * Diagnosis of classical homocystinuria (HCU) * Cohort 7 (currently enrolling): Diagnosis based on clinical, biochemical, and/or molecular genetic testing. * Completed Cohorts 1-6: Genetically confirmed cystathionine beta-synthase (CBS)-deficient HCU. * Plasma total homocysteine (tHcy) * Cohort 7 (currently enrolling): Plasma tHcy ≥50 μM at Screening. * Completed Cohorts 1-6: Plasma tHcy ≥50 μM at Screening and documented historical plasma tHcy ≥80 μM. * Willing and able (or parent/legal guardian willing and able) to provide informed consent/assent and comply with study procedures. * Willing to maintain a generally stable standard-of-care treatment regimen, including dietary management and HCU-related therapies, unless changes are medically necessary. * Participants of childbearing potential must have a negative pregnancy test before study treatment and agree to use protocol-specified contraception, if applicable. Exclusion Criteria: Cohort 7 only: * Diagnosis of Marfan syndrome, methylenetetrahydrofolate reductase (MTHFR) deficiency, or a disorder of cobalamin metabolism. * History of a major thrombotic event within the previous 6 months. * Body weight \<15 kg. All Cohorts: * Previous treatment with pegtibatinase or pegtarviliase) * Participation in a pegtibatinase clinical study. * Receipt of another investigational drug or investigational medical device within 30 days before Screening or planned use during study participation. * Use of injectable polyethylene glycol (PEG)-containing medications (other than pegtibatinase or PEG-containing vaccines) within 3 months before Screening or during study participation. * Known hypersensitivity to pegtibatinase or a history of severe hypersensitivity to a PEG-containing product. * Active HIV, hepatitis B, or hepatitis C infection. * History of organ transplantation or immunosuppressive therapy. * Clinically significant medical conditions that could interfere with study participation or participant safety. * Pregnant or breastfeeding, or planning to become pregnant during study participation. * Major surgery planned during the study period. * Any condition that could prevent the participant from complying with study procedures or completing the study.
Contact & Investigator
Michael Imperiale, MD
STUDY DIRECTOR
Travere Therapeutics, Inc.
Frequently Asked Questions
Who can join the NCT03406611 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 65 Years, studying Homocystinuria. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03406611 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT03406611 currently recruiting?
Yes, NCT03406611 is actively recruiting participants. Contact the research team at medinfo@travere.com for enrollment information.
Where is the NCT03406611 trial being conducted?
This trial is being conducted at Aurora, United States, Miami, United States, Chicago, United States, Indianapolis, United States and 8 additional locations.
Who is sponsoring the NCT03406611 clinical trial?
NCT03406611 is sponsored by Travere Therapeutics, Inc.. The principal investigator is Michael Imperiale, MD at Travere Therapeutics, Inc.. The trial plans to enroll 39 participants.